Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics

H Engel1,2, C Kleespies1, J Friedrich1, M Breidenbach1, A Kallenborn1, T Schöndorf1, H Kolhagen1 and P Mallmann1

1Department of Gynaecology and Obstetrics, University of Cologne, Germany; 2Department of Haematology and Oncology, Medical School Hannover, Carl-Neuberg-Strasse 1, 30623 Hannover, Germany

Summary Detection of micrometastases in patients with solid tumours may aid the establishment of prognosis and development of new therapeutic approaches. This study was designed to investigate the presence and frequency of tumour cells in the peripheral blood (PB) of patients with breast or ovarian cancer by using a combination of magnetic activated cell sorting (MACS) and fluorescence in situ hybridization (FISH). Separated tumour cell and PB-samples from 48 patients (35 breast cancers, 12 ovarian tumours, one uterine sarcoma) were analysed for the presence of numerical aberrations of chromosomes 7, 12, 17 and 17q11.2–q12. Twenty-five patients had primary disease and 23 had relapsed. The technique allows the detection of one tumour cell in 10^6 normal cells. Circulating tumour cells were detected in 35/48 cases (17 patients had relapsed and 13 primary carcinoma with lymph node or solid metastases) by the expression of anti-cytokeratin and the presence of numerical chromosomal abnormalities. PB-tumour cells of patients with a primary carcinoma and without solid metastases had a significantly lower percentage of chromosomal aberrations, especially for chromosome 12 (P = 0.035; P = 0.038) compared to those with relapsed disease and solid metastases. Detection and quantification of minimal residual disease may monitor the response to cytotoxic or hormonal therapy and may identify women at risk of relapse. © 1999 Cancer Research Campaign

Keywords: circulating tumour cells; MACS; FISH

The detection and elimination of minimal disseminated disease in patients with solid tumours is one of the main current topics in clinical oncology (Pantel, 1996). A variety of assays of widely varying sensitivity have been utilized for the detection of circulating tumour cells such as light microscopy, cytogenetic analyses, fluorescence in situ hybridization (FISH), Southern blot analysis, immunocytochemistry, polymerase chain reaction (PCR) and flow cytometry (Kvalheim, 1996; Pantel, 1996; Vrendenburgh et al, 1996; Schoenfeld et al, 1997; Traystman et al, 1997).

Because of the fact that breast and ovarian cancers do not appear to have tumour-specific chromosomal aberrations, tumour cell detection by molecular methods is based on the amplification of tissue-specific transcripts (Mapara et al, 1997; Bostick et al, 1998). In immunocytochemical assays, epithelial specific antibodies have been used to detect isolated tumour cells in bone marrow (BM) and blood (Cote et al, 1991, 1995, 1996; Diel et al, 1996; Franklin et al, 1996).

In an effort to obtain greater sensitivity, several investigators have developed techniques for the enrichment of tumour cells before their identification by immunocytochemistry, PCR or FISH (Hardingham et al, 1993, 1995; Berois et al, 1997; Eaton et al, 1997; Hildebrandt et al, 1997; Naume et al, 1997; Martin et al, 1998).

Therefore, the aim of our study was to analyse the presence and frequency of circulating tumour cells in the peripheral blood of patients with breast or ovarian cancer by using a combination of magnetic activated cell sorting (MACS) and interphase FISH.

MATERIALS AND METHODS

Patients

In this study we included 48 adult patients with a median age of 60.6 ± 13.3 years (range 30–86). Thirty-five had the diagnosis of breast cancer, 12 ovarian cancer and one uterine sarcoma. Twenty-five patients had primary disease (6/25 without involvement of axillary lymph nodes, 8/25 with solid metastases, 11/25 with lymph node metastases) and 23 had relapsed (20/23 with solid metastases). PB-samples were obtained following informed consent at the time of diagnosis, during or after therapy. MACS-sorted tumour cells were analysed by interphase FISH, using α-satellite probes specific for the centromeric regions of chromosomes 7, 12, 17 and the region 17q11.2–q12 (HER-2/neu). Controls were PB-samples from five normal volunteers to determine the background for each probe.

Magnetic cell separation

Mononuclear cells were isolated from fresh blood by Ficoll-Hypaque gradient separation. After washing in PBS per 5 mm EDTA, 300 μl PBS buffer per 10^6 cells, 20 μl of CK-8 microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) were added. After gentle mixing and incubation for 15 min at 4°C, the cells were washed once in 5 ml buffer per 10^6 cells. The buffer was completely removed, and the cells were resuspended again in 400 μl buffer. The cell suspension was then applied to a prefilled
MiniMACS column [MS+RS+ or MACS VS+ separation columns (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)]. The cells were passed through the column and washed four times with 500 μl buffer. The column was removed from the separator, and the CK-enriched cells were eluted using the plunger.

**Flow cytometry**

The following directly conjugated antibodies [anti-cytokeratin (Dako AS, Glostrup, Denmark) and anti-CD45 (Becton Dickinson, Heidelberg, Germany)] were used to detect circulating

---

**Table 1**  
Anatomical site, pathology and percentage of chromosomal aberrations in PB-tumour cells from 45 patients with gynaecological cancer

| Patient no. | Diagnosis                  | Stage | Grade | Metastases | Chromosome 7 (%) | Chromosome 12 (%) | Chromosome 17 (%) |
|-------------|----------------------------|-------|-------|------------|------------------|-------------------|------------------|
| 1           | Breast cancer (relapse)    | I     | G I   | Solid      | 7.0              | 4.7               | 17.5             |
| 2           | Primary breast cancer      | I     | ND    | None       |                  |                   |                  |
| 2a          | Primary breast cancer      | I     | ND    | None       | 3.0 (negative)   | 3.7 (negative)    | 14.3             |
| 2b          | Primary breast cancer      | I     | ND    | None       | 6.3              | 3.7 (negative)    | 15.3             |
| 2c          | Primary breast cancer      | I     | ND    | None       | 7.6              | 11.0              | 13.3             |
| 2d          | Primary breast cancer      | I     | ND    | None       | 6.0              | 3.0 (negative)    | 10.5             |
| 3           | Breast cancer (relapse)    | I     | G II  | Lymph nodes | 5.3 (negative)   | 9.0               | 14.0             |
| 4           | Ovarian cancer (relapse)   | II    | ND    | Solid      | 5.7              | 5.7 (negative)    | 12.0             |
| 5           | Breast cancer (relapse)    | I     | G II  | Solid      | 4.3 (negative)   | 6.5 (negative)    | ND               |
| 6           | Primary ovarian cancer     | IV    | ND    | Solid      | 2.7 (negative)   | 5.7 (negative)    | 15.5             |
| 7           | Primary ovarian cancer     | IV    | ND    | Solid      | 5.1 (negative)   | 4.7 (negative)    | 11.4             |
| 8           | Primary breast cancer      | II    | ND    | Lymph nodes | 4.0 (negative)   | 5.3 (negative)    | 8.7 (negative)   |
| 9           | Ovarian cancer (relapse)   | III   | ND    | Solid      | 4.7 (negative)   | 7.3               | 12.3             |
| 10          | Primary breast cancer      | II    | G III | Lymph nodes | 6.3              | 6.3 (negative)    | 14.3             |
| 11          | Breast cancer (relapse)    | IV    | ND    | Solid      | 4.0 (negative)   | 11.0              | 10.7             |
| 12          | Primary breast cancer      | I     | G II  | Lymph nodes | ND               | ND                | 18.0             |
| 13          | Breast cancer (relapse)    | III   | ND    | Solid      | 4.7 (negative)   | 5.7 (negative)    | 8.6 (negative)   |
| 14          | Primary breast cancer      | II    | G II  | Lymph nodes | 7.7              | 12.0              | 16.0             |
| 15          | Primary breast cancer      | IV    | G II  | Solid      | 5.0 (negative)   | 5.7 (negative)    | 11.0             |
| 16          | Breast cancer (relapse)    | II    | G III | Solid      | 3.7 (negative)   | 8.3               | 17.0             |
| 17          | Primary breast cancer      | I     | G II  | Lymph nodes | 0                | 8.5               | ND               |
| 18          | Ovarian cancer (relapse)   | IV    | G II  | Solid      | 2.3 (negative)   | 13.0              | 22.0             |
| 19          | Primary breast cancer      | IV    | ND    | Lymph nodes | ND               | ND                | 4.2 (negative)   |
| 20          | Breast cancer (relapse)    | I     | ND    | Solid      | 28.1             | 22.8              | ND               |
| 21          | Primary breast cancer      | II    | G I   | None       | ND               | 4.4 (negative)    | ND               |
| 22          | Ovarian cancer (relapse)   | IV    | ND    | Solid      | 0                | ND                | ND               |
| 23          | Breast cancer (relapse)    | IV    | G I   | None       | 4.0 (negative)   | 10.0              | ND               |
| 24          | Ovarian cancer (relapse)   | III   | ND    | Solid      | 1.3 (negative)   | 6.7               | 9.7              |
| 25          | Breast cancer (relapse)    | IV    | ND    | Solid      | 4.8 (negative)   | 6.0 (negative)    | ND               |
| 26          | Primary breast cancer      | IV    | ND    | Solid      | 13.0             | 15.0              | ND               |
| 27          | Primary breast cancer      | II    | G II  | Lymph nodes | 5.0 (negative)   | 6.0 (negative)    | 14.5             |
| 28          | Breast cancer (relapse)    | II    | G II  | Solid      | 7.6              | 15.1              | ND               |
| 29          | Primary breast cancer      | II    | G II  | None       | 7.3              | 5.3 (negative)    | 14.7             |
| 30          | Primary breast cancer      | II    | ND    | None       | 3.0 (negative)   | 3.0 (negative)    | 13.0             |
| 31          | Primary breast cancer      | I     | ND    | None       | 4.7 (negative)   | 3.0 (negative)    | 14.0             |
| 32          | Primary breast cancer      | I     | G II  | Lymph nodes | 7.0              | 7.0               | 10.0             |
| 33          | Primary breast cancer      | IV    | ND    | Lymph nodes | ND               | ND                | 13.7             |
| 34          | Primary ovarian cancer     | III   | G II  | Solid      | 1.5 (negative)   | 4.6 (negative)    | ND               |
| 35          | Primary ovarian cancer     | III   | ND    | Solid      | 6.0              | 11.3              | 14.3             |
| 36          | Breast cancer (relapse)    | I     | G III | None       | 7.0              | 9.3               | 11.5             |
| 37          | Primary ovarian cancer     | II    | G III | Lymph nodes | 0                | 3.4 (negative)    | ND               |
| 38          | Primary breast cancer      | II    | G III | Solid      | 1.3 (negative)   | 9.3               | 10.5             |
| 39          | Primary breast cancer      | I     | ND    | None       | 3.3 (negative)   | 3.7 (negative)    | 10.7             |
| 40          | Primary breast cancer      | I     | ND    | None       | 5.5              | 5.5 (negative)    | 10.7             |
| 41          | Ovarian cancer (relapse)   | III   | ND    | Solid      | 0                | 7.0               | ND               |
| 42          | Breast cancer (relapse)    | II    | ND    | Solid      | 0                | 10.0              | ND               |
| 43          | Uterus sarcoma (relapse)   | II    | G III | Solid      | 6.0              | 18.0              | ND               |
| 44          | Ovarian cancer (relapse)   | IV    | ND    | Solid      | 4.9 (negative)   | 9.2               | ND               |
| 45          | Primary breast cancer      | I     | G III | Lymph nodes | negative      | negative          | negative         |
| 46          | Primary breast cancer      | I     | G II  | Lymph nodes | negative      | negative          | negative         |
| 47          | Breast cancer (relapse)    | II    | ND    | Solid      | negative      | negative          | negative         |
| 48          | Breast cancer (relapse)    | II    | ND    | Solid      | negative      | negative          | negative         |
|             |                           |       |       |            | Mean ± s.e.m.   | 5.0 ± 0.7          | 7.7 ± 0.7         | 12.9 ± 0.6        |

ND, not determined; *Percentage of chromosomal aberrations less than background (mean + 3 SD of normal control cells)
tumour cells. A total of 10 μl of anti-CD45 PerCP (peridinin–chlorophyll–protein) conjugated antibody were added to 1 × 10^6 mononuclear cells and incubated for 15 min at room temperature in darkness. Appropriate isotype controls were used to set the amplification and compensation of the flow cytometer. The cells were then washed twice with PBS and fixed in 1 ml 0.25% paraformaldehyde at room temperature for 15 min. After another wash with PBS, cells were incubated in cold (4°C) 70% methanol for 60 min in darkness before staining with 10 μl anti-cytokeratin FITC (fluorescein isothiocyanate)-labelled antibody. After an incubation of 30 min at 4°C, the cells were washed with PBS, resuspended in 300 μl PBS and then analysed with a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). Analysis by flow cytometry was done before and after MACS-sorting. Tumour cells were defined as cytokeratin+/CD45–.

Fluorescence in situ hybridization

Sorted cells were fixed in 3:1 methanol:glacial acetic acid and stored until hybridization at −20°C. Slides were incubated at room temperature in 0.1 N hydrochloric acid with 0.05% Triton X-100 for 15 min and then washed six times: once for 2 min in 2 × saline sodium citrate (SSC; 0.3 M sodium chloride, 30 mM sodium citrate, pH 7), once in PBS, once in PBS with 1% formaldehyde for 5 min, twice for 2 min with PBS, and finally once with 2 × SSC. Slides were denatured in 70% formamide in 2 × SSC at 70°C for 2–4 min, dehydrated in a 70%, 85%, 100% ethanol series and air-dried.

Directly conjugated centromeric probes (CEP) specific for chromosomes 7, 12 and 17 (Vysis, Stuttgart, Germany) were used for interphase FISH (CEP 7 conjugated to Spectrum Green, CEP 12 and 17 conjugated to Spectrum Orange, CEP 17/17q.11.2–q12 conjugated to Spectrum Green/Orange). One microlitre of each probe was mixed with 7 μl hybridization buffer (50% formamide, 2 × SSC, 10% dextran sulphate) and 2 μl distilled water. Probe DNA was denatured for 5 min at 70°C and applied to each slide. Hybridization was performed overnight at 37°C in a humidified chamber.

Non-hybridized probe was washed off by a series of three post-hybridization washes in 50% formamide in 2 × SSC at 45°C each for 10 min, followed by one 10-minute wash in 2 × SSC and one 5-min wash in 2 × SSC/0.1% NP-40 at 37°C. The nuclei were counterstained with diamin-2-phenylindole dihydrochloride (DAPI, 0.2 μM in 90% glycerol/10% PBS, pH 8.0). Hybridization signals were counted by hand in 100–500 cells under a fluorescence microscope (Leica, Heerbrugg, Switzerland) equipped with a triple filter set (DAPI/FITC/Texas-Red).
Statistical analysis

Data are expressed as mean (± s.e.m.) or as mean (± s.d.) and analysed by using the two-way analysis of variance and other standard methods. The SPSS statistical package was employed for these analyses as well as to generate descriptive statistics of the data.

RESULTS

We investigated 48 patients with gynaecological cancer (Table 1). To obtain greater sensitivity, we applied FISH on MACS-sorted cells. To distinguish monosomy and trisomy from background, cut-off levels were set at 3 standard deviations (s.d.) above the mean percentages of normal control cells (\( n = 5 \)) with one or three signals (> 5.3% for abnormalities of chromosome 7, > 6.3% for abnormalities of chromosome 12, > 8.2% for abnormalities of chromosome 17).

FISH on primary tumours and cell lines

As a positive control for aberrations of chromosomes 7, 12 and 17 we analysed a breast cancer (MCF-7) and an ovarian cancer cell line (MZ-1b). All MCF-7 and MZ-1b cells were aberrant for chromosomes 7 and 12 and 87.5% of these cells showed numerical abnormalities for chromosome 17. SK-BR-3 human breast cancer cells (97% of aberrant tumour-cell nuclei) were used as a control for Her-2/neu amplification.

Tumour cells obtained from tissue or effusions (\( n = 10 \)) showed a high frequency of chromosomal aberrations (an average of 45%) mainly trisomies and tetrasomies of chromosomes 7, 12 and 17. A monosomy pattern was limited to chromosome 17. Her-2/neu amplification was identified on average in 36% of tumour-cell nuclei with high copy levels.

Sensitivity

Dilution experiments were performed to determine the sensitivity of FISH after MACS-sorting. MCF-7 cells with an average of 98% of numerical aberrations for chromosomes 7 and 12 (trisomies and tetrasomies) were sorted into normal peripheral blood (0.1–10\( ^{-6} \)). By comparing flow cytometry after MACS-sorting using an anticytokeratin and an anti-CD45 antibody and FISH (\( \alpha \)-satellite probes for chromosomes 7, 12 and 17), flow cytometry failed to detect tumour cells at a level of 5 \( \times 10^{-4} \). With FISH we were able to identify 2.4% of chromosomal aberrant cells in a dilution containing as few as 1 tumour cell in 10\( ^{6} \) normal cells (Figure 1 and Table 2).

Flow cytometry after MACS-sorting of PB-tumour cells

On 12 samples from 9/25 patients with primary carcinoma, we applied flow cytometry after MACS-sorting by doublestaining with anti-FITC-conjugated anti-cytokeratin and anti-PerCP-conjugated CD45 antibody. Tumour cells were defined as CK+/CD45−. The purity ranged from 0.04% to 18.50% (median: 7.30%; Table 3 and Figure 2). Some cells even double expressed CK and CD45, suggesting a false-positive detection of tumour cells. There was no correlation between sorting purity and the frequency of chromosomal aberrations detected by FISH.

Table 2 Dilution experiment of normal peripheral blood containing MCF-7 cells

| Dilution | Chromosome 7 (%) | Chromosome 12 (%) | Cytokeratin+ cells (%) | Flow cytometry |
|----------|----------------|----------------|------------------------|---------------|
|          | (% abnormal cells) | (% abnormal cells) |                        |               |
| 100      | 98.7            | 98.4           | 98.2                   |               |
| 0.1      | 65              | 66             | 95.4                   |               |
| 10\(^{-2}\) | 55            | 55             | 76.8                   |               |
| 5 \( \times 10^{-3}\) | 60            | 60             | 56.3                   |               |
| 10\(^{-3}\) | 32            | 29             | 22.2                   |               |
| 5 \( \times 10^{-4}\) | 9             | 9.2            | 0                      |               |
| 10\(^{-4}\) | 2.7           | 2.7            | 0                      |               |
| 5 \( \times 10^{-5}\) | 5.2           | 8.4            | 0                      |               |
| 10\(^{-5}\) | 3.1           | 3.4            | 0                      |               |
| 5 \( \times 10^{-6}\) | 0.5           | 0.8            | 0                      |               |
| 10\(^{-6}\) | 2.2\(^{f}\)    | 2.4\(^{f}\)    | 0                      |               |

\(^{a}\)NPB; normal peripheral blood; \(^{b}\)at least 300 cells were counted; \(^{c}\)cells with trisomies or tetrasomies; \(^{d}\)10 000 events were acquired; \(^{e}\)background trisomy 7: 1.32%; \(^{f}\)background trisomy 12: 1.10%.

Table 3 Flow cytometry and FISH including HER-2/neu after MACS-sorting of PB-tumour cells from 10/28 patients with primary carcinoma

| Patient no. | CK (%) | Aberrant cells (%) |
|-------------|--------|--------------------|
|             | Chromosome 7 | Chromosome 12 | Chromosome 17 | Her-2/neu |
| 2a          | 18.5    | 3.0 (negative\(^{a}\)) | 3.7 (negative\(^{a}\)) | 14.3 | 18.8 |
| 2b          | 10.8    | 6.3               | 3.7           | 15.3 | 16.7 |
| 2c          | 13.3    | 7.6               | 11.0          | ND   | 36.4 |
| 2d          | 1.92    | 6.0               | 3.0 (negative\(^{a}\)) | 10.5 | negative |
| 12          | 0.08    | ND                | ND            | 18.0 | 46.2 |
| 17          | 2.8     | 0                 | 8.5           | ND   | ND   |
| 19          | 0.04    | ND                | ND            | 4.2 (negative\(^{a}\)) | 22.7 |
| 21          | 7.3     | ND                | 4.4 (negative\(^{a}\)) | ND   | ND   |
| 30          | 10.0    | 3.0               | 3.0 (negative\(^{a}\)) | 13.0 | ND   |
| 33          | 7.7     | ND                | ND            | 13.7 | 41.5 |
| 34          | 13.0    | 1.5               | 4.6 (negative\(^{a}\)) | ND   | ND   |
| 41          | 2.1     | 0                 | 7.0           | ND   | ND   |

Mean ± s.e.m. 6.9 ± 1.6 | 3.4 ± 1.0 | 5.4 ± 0.9 | 12.7 ± 1.7 | 30.4 ± 5.1

ND, not determined; \(^{a}\)Percentage of chromosomal aberrations less than background (mean + 3 SD of normal control cells)

Table 3 Flow cytometry and FISH including HER-2/neu after MACS-sorting of PB-tumour cells from 10/28 patients with primary carcinoma

| Patient no. | CK (%) | Aberrant cells (%) |
|-------------|--------|--------------------|
|             | Chromosome 7 | Chromosome 12 | Chromosome 17 | Her-2/neu |
| 2a          | 18.5    | 3.0 (negative\(^{a}\)) | 3.7 (negative\(^{a}\)) | 14.3 | 18.8 |
| 2b          | 10.8    | 6.3               | 3.7           | 15.3 | 16.7 |
| 2c          | 13.3    | 7.6               | 11.0          | ND   | 36.4 |
| 2d          | 1.92    | 6.0               | 3.0 (negative\(^{a}\)) | 10.5 | negative |
| 12          | 0.08    | ND                | ND            | 18.0 | 46.2 |
| 17          | 2.8     | 0                 | 8.5           | ND   | ND   |
| 19          | 0.04    | ND                | ND            | 4.2 (negative\(^{a}\)) | 22.7 |
| 21          | 7.3     | ND                | 4.4 (negative\(^{a}\)) | ND   | ND   |
| 30          | 10.0    | 3.0               | 3.0 (negative\(^{a}\)) | 13.0 | ND   |
| 33          | 7.7     | ND                | ND            | 13.7 | 41.5 |
| 34          | 13.0    | 1.5               | 4.6 (negative\(^{a}\)) | ND   | ND   |
| 41          | 2.1     | 0                 | 7.0           | ND   | ND   |

Mean ± s.e.m. 6.9 ± 1.6 | 3.4 ± 1.0 | 5.4 ± 0.9 | 12.7 ± 1.7 | 30.4 ± 5.1

ND, not determined; \(^{a}\)Percentage of chromosomal aberrations less than background (mean + 3 SD of normal control cells)
Figure 2  Flow cytometry before and after MACS-sorting of peripheral blood cells. Application of flow cytometry before (A–C) and after MACS-sorting (D–F) by doublestaining with anti-FITC conjugated anti-cytokeratin and anti-PerCP-conjugated CD45 antibody. Tumour cells were defined as CK+/CD45−. Before MACS-sorting (B, C) 0.7% of CK+/CD45− cells (R2 and R3). After enrichment a high contamination with leucocytes (E); all cells located in R2 expressed CK but were also CD45+ (F), suggesting a high rate of false-positive results.
FISH on MACS-sorted PB-tumour cells

In 35/48 peripheral blood samples (17 patients had relapsed and 13 primary carcinoma with lymph node or solid metastases) we were able to detect tumour cells which carried chromosomal aberrations; they were identified by the fluorescence pattern of their nuclei (Table 1 and Figure 3). To confirm the presence of tumour cells after MACS-sorting, cells were doublestained for anti-cytokeratin and anti-CD45. These cells showed aberrations appearing mainly as monosomies for chromosome 17 (12.93% ± 0.59%) and as trisomies for chromosomes 7 and 12 (5.04% ± 0.68% and 7.64% ± 0.66%). Tumour cells from six PB-samples (primary carcinoma) were also studied for amplification of the region 17q11.2–q12 (Table 3 and Figure 3). The frequency of aberrations (30.36% ± 5.13%) was much higher than numerical changes of chromosomes 7, 12 and 17.

PB-tumour cells from patients with a primary carcinoma without solid metastases had a significantly lower percentage of chromosomal aberrations, especially for chromosome 12 (P = 0.035) compared to those with relapsed disease and solid metastases (Figures 4 and 5). There was no statistically significant difference in the frequency of chromosomal aberrations with respect to lymph node involvement in patients with primary carcinoma. Twelve out of 25 patients with a primary carcinoma are still in clinical remission with a median follow-up of 20 months (range 4–24 months), one patient died in clinical remission (CR) after 2 months, four relapsed after a median CR duration of 11 months (range 5–12 months). There was no correlation between the frequency of chromosomal aberration in PB-tumour cells and remission duration. Five of 8 patients with primary carcinoma and solid metastases have stable disease with a median follow-up of 19 months (range 9–22 months), one patient has progressive disease and two patients died shortly after diagnosis because of their metastases.

In 13/48 samples (seven patients with primary carcinoma and four of them without lymph node involvement, six patients with relapsed disease and solid metastases) we could not detect tumour cells either by flow cytometry or by FISH. The six patients with solid metastases are clinically unchanged (median follow-up 24 months); three patients are in CR (median follow-up months), one patient died after 2 months in CR and three patients relapsed after a median remission duration of 5 months.

Tumour cell detection in peripheral blood and bone marrow: a follow-up of a patient with primary breast cancer

Four PB and one BM sample were obtained from a patient with primary breast cancer (patient no. 2, Tables 1 and 3) at diagnosis and at three different time points after surgery. The patient did not receive any chemotherapy or hormonal treatment.
Cells were doublestained for anti-cytokeratin and anti-CD45 before MACS-sorting. By flow cytometry we were able to detect 23 tumour cells µl⁻¹ in the first PB-sample (obtained before tumour resection), one tumour cell µl⁻¹ 4 months after surgery, two tumour cells µl⁻¹ in a follow-up sample 8 months after diagnosis compared to 104 tumour cells µl⁻¹ in the bone marrow. We could not detect any CK/CD45⁺ cells in a PB-sample obtained 14 months after diagnosis. However, by applying FISH after MACS-sorting we identified peripheral blood tumour cells with aberrations for chromosome 7 (5.8% ± 1.0%), chromosome 12 (5.3% ± 1.9%), chromosome 17 (13.4% ± 1.0%) and for the region 17q11.2–q12 (23.9% ± 6.3%) without any statistically significant differences between the first three samples (Tables 1 and 2). The frequency of aberrant tumour cells was lower in the fourth sample and no Her-2/neu amplification could be detected. BM tumour cells showed in 11.8%, numerical aberrations for the centromeric region of chromosome 17 and amplification for Her-2/neu in 18.2%.

**DISCUSSION**

The detection of small numbers of carcinoma cells in patients with solid tumours has become increasingly important and may help in determining the prognosis and the development of new therapeutic approaches (Datta et al, 1994; Ross, 1998).

Many techniques such as immunocytochemistry, flow cytometry, PCR and FISH have been used to detect micrometastases in peripheral blood, bone marrow, aphereses or lymph nodes (Smith et al, 1991; Kvalheim, 1996; Pantel, 1996; Vrendenburgh et al, 1991; Schoenfeld et al, 1997; Traystman et al, 1997).

In immunocytochemical assays, monoclonal antibodies to cytokeratins can be regarded as a sensitive probe to detect isolated epithelial tumour cells in bone marrow and blood (Diel et al, 1996; Franklin et al, 1996).

Molecular methods are based on the detection of either mutations in oncogenes and tumour suppressor genes or mRNA expression of tissue-specific and tumour-associated genes (Datta et al, 1994; Schoenfeld et al, 1994, 1997; Krugger et al, 1996; Luppi et al, 1996; Moscinski et al, 1996; Noguchi et al, 1996). Nevertheless, the immunocytochemistry method needs to be further developed before it can be used routinely in the clinic and it is not clear whether the most frequently employed reverse transcription PCR (RT-PCR) assays for cytokeratin 18 or 19 or pancarcinoma-associated tumour marker (KSA or 17-1A antigen) have the specificity to be reliably used (Kvalheim, 1996; Helfrich et al, 1997).

Human breast and ovarian cancers appear, despite their considerable pathologic uniformity, to be heterogeneous with respect to biological and clinical behaviour and these tumours are not associated with unique karyotypic changes (Deville et al, 1988). Conventional cytogenetic studies and FISH analyses of breast and ovarian tumour cells have shown multiple chromosomal abnormalities involving chromosomes 7, 12 and 17 (Dutrillaux et al, 1990; Geleick et al, 1990; Cajulis et al, 1994; Persons 1994; Xu et al, 1994; Fiegl et al, 1995; Visscher et al, 1995, 1996; Ishikawa et al, 1996, Engel et al, 1998). The erbB-2 oncogene located on chromosome 17q is expressed in a substantial number of breast tumours and associated with a poor prognosis (Kallioniemi et al, 1992; An et al, 1995; Schildkraut et al, 1995; Fernandez et al, 1996; Sauter et al, 1996; Ishikawa et al, 1997). Recent studies (Press et al, 1997; Revillion et al, 1998) have confirmed a significantly worse survival of erbB-2-positive patients and suggest that erbB-2 could be a marker of reduced response to chemotherapy and hormonal treatment.

Fluorescence in situ hybridization, by which many cells can be screened, independent of their capacity to proliferate in vitro, has become a complementary tool in cancer cytogenetics for the detection of numerical aberrations in interphase nuclei and for the classification of marker chromosomes (Kiechle-Schwarz et al, 1991; Le Beau, 1993; Micale et al, 1994; Muller et al, 1996).

The immunomagnetic MACS system, using magnetic beads coated with a cocktail of monoclonal antibodies recognizing the leucocyte common antigen CD45 or the CK-antigen developed by Miltenyi et al in 1990, is an extremely efficient method for separating cells (Harbeck et al, 1995). No morphological alterations were observed after the separation, which suggests that the passage through a strong magnetic field does not damage the cells.

In this study, we used FISH on MACS-sorted tumour cells to investigate the presence and frequency of micrometastases in patients with breast or ovarian cancer by using CK-8 microbeads and 0-satellite probes specific for the centromeric regions of chromosomes 7, 12 and 17 and the region 17q11.2–q12 (HER-2/neu).

Trisomies and tetrasomies of chromosomes 7, 12 and 17, as well as combined aberrations, have been identified by FISH in a substantial number of tumour cells obtained from tumour tissue. A monosomy pattern was limited primarily to chromosome 17, thus correlating with previous cytogenetic studies (Visscher et al, 1996; Engel et al, 1998).

Circulating tumour cells were present in 35/48 peripheral blood samples. Flow cytometry after MACS-sorting failed at a detection level of 5 × 10⁻⁴. The sorting purity ranged from 0.04% to 18.50% in patients samples, suggesting a low degree of specificity and substantial contamination with normal PB lymphocytes. FISH after MACS-sorting is an alternative method for detection of circulating tumour cells with a higher sensitivity (one tumour cells 10⁸ normal cells). However, PB-tumour cells carried aberrations for chromosomes 7, 12 and 17 as well but at a much lower frequency (especially for chromosomes 7 and 12) compared to those obtained from tumour tissue. In fact, these very low rates of aberrations might suggest that chromosomes 7 and 12 are less frequently involved in micrometastases of patients with breast or ovarian cancer. On the other hand, it is tempting to speculate that PB-tumour cells might be different with respect to their biological behaviour. Nevertheless, higher levels of Her-2/neu copies (on average 30%) and numerical aberrations for the centromeric region of chromosome 17 (on average 13%) were detected, suggesting chromosome 17 is frequently involved and might be a sensitive marker for the detection of circulating tumour cells. However, follow-up samples at different time points in clinical remission are necessary to prove the value of circulating tumour cells.

The technique described could become a valuable tool for the quantification and molecular characterization of metastatic carcinoma cells and might provide the basis to monitor the response to cytotoxic or hormonal therapy and may identify women at risk of relapse.

**REFERENCES**

An HX, Niederacher D, Beckmann MW, Gohring UI, Scharl A, Picard F, van Roeyen C, Schnurch HG and Bender HG (1995) ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. Int J Cancer 64, 291–297
Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R and Hoon DS (1997) Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res 53: 3455–3458

Helfrich W, ten Poole R, Meersma GT, Mulder NH, de Vries EJ, de Leij L and Smit AM (1996) A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood. Br J Cancer 76: 29–35

Hildebrandt M, Mapara MY, Korner IJ, Bargou RC, Molenhauer G and Dorken B (1997) Reverse transcriptase-polymerase chain reaction (RT-PCR)-controlled immunomagnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: a sensitive method for monitoring purging efficiency. Exp Hematol 25: 57–65

Ishikawa D, Hashimoto N, Hashioka M, Yamaguchi T, Sawai K, Nakamura Y, Fakih Abbas A, Beiske K and Inagawa J (1997) Analysis of numerical aberrations of specific chromosomes by fluorescence in situ hybridization as a diagnostic tool in breast cancer. Cancer 77: 2064–2069

Ishikawa T, Kobayashi M, Mai M, Suzuki T and Ooi A (1997) Amplification of the c-erbB-2 (Her-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol 151: 761–768

Kallioniemi OP, Kallioniemi A, Kurki S, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D and type II ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89: 5321–5325

Kiechle-Schwarz M, Decker HH, Berger CS, Fiebig CS and Sandberg AA (1991) Detection of monosomy in interphase nuclei and identification of marker chromosomes using biotinylated alpha-satellite DNA probes. Cancer Genet Cytogenet 51: 23–33

Kruger W, Krizanzanowski C, Holweg M, Stockschlader M, Kroger N, Jung R, Mross K, Jonat W and Zander AR (1996) Reverse transcription-polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol 122: 679–686

Kreuder WM, Stockschlader M, Hennings S, Aschenbrenner M, Gruber M, Gutensohn K, Koliger C, Gieseking F, Jonat W and Zander AR (1996) Detection of cancer cells in peripheral blood of women with breast cancer by RT-PCR and cell culture. Bone Marrow Transplant 18: 18–20

Kvalheim G (1996) Detection of occult tumour cells in bone marrow and blood in breast cancer patients – methods and clinical significance. Acta Oncol 35: 13–18

Le Beau MM (1993) Detecting genetic changes in human tumor cells: Have scientists 'gone fishing'? Blood 81: 1979–1983

Luppi M, Morselli M, Bandieri E, Federico M, Marasca R, Barozzi P, Ferrari MG, Savarino M, Frassoldati A and Torelli G (1996) Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Am J Oncol 7: 619–624

Mapara MY, Korner IJ, Hildebrandt M, Bargou R, Krahl D, Reichardt P and Dorken B (1997) Monitoring of tumor cell purging after highly enriched efficient immunoselection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 89: 337–344

Martin VM, Siewert C, Schaf A, Harms R, Heine R, Ohl S, Radbruch A, Milteny S and Schmitz J (1998) Immunomagnetic enrichment of disseminated epithelial cells in breast cancer bone marrow. Exp Hematol 26: 252–264

Micalae MV, Vischer DW, Gulino SE and Wolman SR (1994) Chromosomal aneuploidy in proliferative breast disease. Human Pathol 25: 29–35

Milteny S, Muller W, Weichel W and Radbruch A (1990) High gradient magnetic cell separation technique (MACS). J Cancer Res Clin Oncol 116: 159–165

Muller P, Weckermann D, Riethmüller G and Schlimok G (1996) Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 88: 8–16

Naume B, Borgen E, Beiske K, Herstad TK, Ravns G, Renolen A, Trachsel S, Thrane-Steen K, Punderud S and Kvalheim G (1997) Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 6: 103–114

Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S and Koyama H (1996) Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. Am J Pathol 148: 649–656

Pantel K (1996) Detection of minimal residual disease in patients with solid tumors. J Hematother 5: 359–367

Persons DL, Hartmann LC, Herath JF, Keene GL and Jenkins RB (1994) Fluorescence in situ hybridization analysis of trisomy 12 in ovarian tumors. Am J Pathol 144: 775–779

Press MF, Bernstein L, Thomas PA, Meissner LF, Zhou YJ, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar AK, Slamovitch D, Phillips BN, Ross JS, Wolman SR and Flom KJ (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894–2904
